BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, announced today that it will host a conference call and webcast to provide a business update on Monday, August 19, 2024 at 4:30 p.m. EDT. Live and archived versions of the event can be accessed via the Company’s website.
The company will provide a business overview of its recent restructuring and near-term strategic prioritization objectives. The discussion will focus on the company’s approach to enhance near-term shareholder value by refocusing resources on further development of its ongoing autoimmune programs, CUE-401 and CUE-501, while enabling data from its ongoing oncology trials for CUE-101 and CUE-102 to continue to mature. Additional clinical and business updates, as well as market opportunities and anticipated near-term milestones, will also be addressed.
Webcast Details
Monday, August 19 at 4:30 p.m. EDT
| Investors: | 1-844-826-3035 | |
| International Investors: | 1-412-317-5195 | |
| Conference ID: | 10191414 | |
| Request a return call via the Call me™ link: | https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg== | |
| Participants can use guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The link will be active 15 minutes prior to the scheduled start time. | ||
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1682217&tp_key=cc61641c8f | |
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
